← Back to patent-cliff list
Sapanisertib/Serabelisib
Tier C — Watch / tradeSapanisertib/Serabelisib
Faeth Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：mTORC1, mTORC2, PI3Kα
Indications (approved)：Endometrial cancer
Regional status
US
Phase II
2024-12-12
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sapanisertib/Serabelisib?
Approved indications include: Endometrial cancer.
When does the Sapanisertib/Serabelisib patent expire?
No public expiry year is available for Sapanisertib/Serabelisib yet; this page updates once verified.
How do I get a quote for Sapanisertib/Serabelisib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01